Standout Papers

Recommendations for Human Epidermal Growth... 1997 2026 2006 2016 3.0k
  1. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update (2013)
    Antonio C. Wolff, M. Elizabeth Hammond et al. Journal of Clinical Oncology
  2. A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer (2003)
    Umberto Veronesi, Giovanni Paganelli et al. New England Journal of Medicine
  3. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes (1997)
    Umberto Veronesi, Giovanni Paganelli et al. The Lancet
  4. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update (2018)
    Antonio C. Wolff, M. Elizabeth Hammond et al. Journal of Clinical Oncology
  5. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update (2013)
    Antonio C. Wolff, M. Elizabeth Hammond et al. Archives of Pathology & Laboratory Medicine
  6. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 (2013)
    Sherene Loi, Nicolas Sirtaine et al. Journal of Clinical Oncology
  7. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update (2018)
    Antonio C. Wolff, M. Elizabeth Hammond et al. Archives of Pathology & Laboratory Medicine
  8. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer (2017)
    Gϋnter von Minckwitz, Marion Procter et al. New England Journal of Medicine
  9. Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer (2006)
    Marc Buyse, Sherene Loi et al. JNCI Journal of the National Cancer Institute
  10. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update (2020)
    Kimberly H. Allison, M. Elizabeth H. Hammond et al. Journal of Clinical Oncology
  11. Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content (2010)
    Salvatore Pece, Daniela Tosoni et al. Cell
  12. Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series (2007)
    Christine Desmedt, Fanny Piette et al. Clinical Cancer Research
  13. Triple-negative breast cancer: disease entity or title of convenience? (2010)
    Lisa A. Carey, Eric P. Winer et al. Nature Reviews Clinical Oncology
  14. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis (2018)
    Fabio Conforti, Laura Pala et al. The Lancet Oncology
  15. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation (1996)
    Peter Vermeulen, Giampietro Gasparini et al. European Journal of Cancer
  16. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells (2005)
    Monica Rimoldi, Marcello Chieppa et al. Nature Immunology
  17. Sentinel Lymph Node Biopsy and Axillary Dissection in Breast Cancer: Results in a Large Series (1999)
    Umberto Veronesi, Giovanni Paganelli et al. JNCI Journal of the National Cancer Institute
  18. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial (2013)
    Umberto Veronesi, Roberto Orecchia et al. The Lancet Oncology
  19. A gut-vascular barrier controls the systemic dissemination of bacteria (2015)
    Ilaria Spadoni, Elena Zagato et al. Science
  20. HER2-Low Breast Cancer: Pathological and Clinical Landscape (2020)
    Paolo Tarantino, Erika Hamilton et al. Journal of Clinical Oncology
  21. HER2 testing in gastric cancer: a practical approach (2012)
    Josef Rüschoff, Wedad Hanna et al. Modern Pathology
  22. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study (2022)
    Luca Gianni, Chiun‐Sheng Huang et al. Annals of Oncology
  23. Evolution of low HER2 expression between early and advanced-stage breast cancer (2022)
    Paolo Tarantino, Sara Gandini et al. European Journal of Cancer

Immediate Impact

2 by Nobel laureates 14 from Science/Nature 159 standout
Sub-graph 1 of 20

Citing Papers

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
19 intermediate papers

Works of Giuseppe Viale being referenced

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
2018 Standout
Cancer–testis antigen expression in triple-negative breast cancer
2010
and 16 more

Author Peers

Author Last Decade Papers Cites
Giuseppe Viale 28609 25471 12315 12823 766 53.8k
Ian O. Ellis 27787 26157 13790 20054 971 58.9k
Gabriel N. Hortobágyi 53018 36270 12422 22479 1.1k 86.1k
Daniel F. Hayes 25941 20441 6030 12718 407 45.3k
Funda Meric‐Bernstam 16960 14262 7235 11610 860 34.6k
Bernard Fisher 23654 30424 16849 4675 428 50.3k
Larry Norton 29114 15708 4870 13531 528 49.6k
Norman Wolmark 38425 39518 21375 7449 528 67.3k
Razelle Kurzrock 24289 12983 9786 20512 1.2k 58.6k
Gary M. Clark 27959 14287 4975 13822 265 43.7k
Seth M. Steinberg 28549 7768 7877 15293 861 57.6k

All Works

Loading papers...

Rankless by CCL
2026